Growth hormone attenuates tumor necrosis factor in burned children

Minas T. Chrysopoulo, Marc G. Jeschke, Roquc J. Ramirez, Robert E. Barrow, David Herndon

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background: Recombinant human growth hormone (rhGH) has been shown to favorably modulate the acute-phase response and may improve the clinical outcome. Objective: To examine whether rhGH attenuates the elevated tumor necrosis factor α (TNF-α) levels that correlate with increased multiorgan failure and mortality in burned adults and children. Design: Twenty children with burns of greater than 40% of the total body surface area were randomly divided into 2 groups to receive placebo (n = 10) or rhGH, 0.2 mg/kg per day intramuscularly (n = 10). Setting: Pediatric burn hospital. Main Outcome Measure: Serum TNF-α levels by enzyme-linked immunoassay at baseline (day 0) and at 21 and 42 days after injury. For statistical analysis, we used the Kruskal-Wallis and Friedman tests. Results: No significant differences in age (mean ± SD, 6.2 ± 1.6 vs 5.0 ± 1.2 years) or percentage of total body surface area burn (mean ± SD, 65.1% ± 8.2% vs 57.1% ± 5.2%) could be shown between the groups given rhGH and placebo. Baseline TNF-α levels were elevated from reference values in both groups. Twenty-one and 42 days after rhGH administration, serum TNF-α levels were significantly decreased from those at baseline (P<.05). No significant decrease in TNF-α levels was observed in the placebo group (P = .5). Conclusions: Recombinant human growth hormone significantly lowers serum TNF-α levels after burn injury. This is consistent with the beneficial effect that rhGH has on the acute-phase response.

Original languageEnglish (US)
Pages (from-to)283-286
Number of pages4
JournalArchives of Surgery
Volume134
Issue number3
StatePublished - Mar 1999

Fingerprint

Human Growth Hormone
Growth Hormone
Tumor Necrosis Factor-alpha
Acute-Phase Reaction
Body Surface Area
Placebos
Serum
Pediatric Hospitals
Wounds and Injuries
Immunoenzyme Techniques
Burns
Reference Values
Outcome Assessment (Health Care)
Mortality

ASJC Scopus subject areas

  • Surgery

Cite this

Chrysopoulo, M. T., Jeschke, M. G., Ramirez, R. J., Barrow, R. E., & Herndon, D. (1999). Growth hormone attenuates tumor necrosis factor in burned children. Archives of Surgery, 134(3), 283-286.

Growth hormone attenuates tumor necrosis factor in burned children. / Chrysopoulo, Minas T.; Jeschke, Marc G.; Ramirez, Roquc J.; Barrow, Robert E.; Herndon, David.

In: Archives of Surgery, Vol. 134, No. 3, 03.1999, p. 283-286.

Research output: Contribution to journalArticle

Chrysopoulo, MT, Jeschke, MG, Ramirez, RJ, Barrow, RE & Herndon, D 1999, 'Growth hormone attenuates tumor necrosis factor in burned children', Archives of Surgery, vol. 134, no. 3, pp. 283-286.
Chrysopoulo MT, Jeschke MG, Ramirez RJ, Barrow RE, Herndon D. Growth hormone attenuates tumor necrosis factor in burned children. Archives of Surgery. 1999 Mar;134(3):283-286.
Chrysopoulo, Minas T. ; Jeschke, Marc G. ; Ramirez, Roquc J. ; Barrow, Robert E. ; Herndon, David. / Growth hormone attenuates tumor necrosis factor in burned children. In: Archives of Surgery. 1999 ; Vol. 134, No. 3. pp. 283-286.
@article{bcc42cf887ec4f72bc5b79987db54656,
title = "Growth hormone attenuates tumor necrosis factor in burned children",
abstract = "Background: Recombinant human growth hormone (rhGH) has been shown to favorably modulate the acute-phase response and may improve the clinical outcome. Objective: To examine whether rhGH attenuates the elevated tumor necrosis factor α (TNF-α) levels that correlate with increased multiorgan failure and mortality in burned adults and children. Design: Twenty children with burns of greater than 40{\%} of the total body surface area were randomly divided into 2 groups to receive placebo (n = 10) or rhGH, 0.2 mg/kg per day intramuscularly (n = 10). Setting: Pediatric burn hospital. Main Outcome Measure: Serum TNF-α levels by enzyme-linked immunoassay at baseline (day 0) and at 21 and 42 days after injury. For statistical analysis, we used the Kruskal-Wallis and Friedman tests. Results: No significant differences in age (mean ± SD, 6.2 ± 1.6 vs 5.0 ± 1.2 years) or percentage of total body surface area burn (mean ± SD, 65.1{\%} ± 8.2{\%} vs 57.1{\%} ± 5.2{\%}) could be shown between the groups given rhGH and placebo. Baseline TNF-α levels were elevated from reference values in both groups. Twenty-one and 42 days after rhGH administration, serum TNF-α levels were significantly decreased from those at baseline (P<.05). No significant decrease in TNF-α levels was observed in the placebo group (P = .5). Conclusions: Recombinant human growth hormone significantly lowers serum TNF-α levels after burn injury. This is consistent with the beneficial effect that rhGH has on the acute-phase response.",
author = "Chrysopoulo, {Minas T.} and Jeschke, {Marc G.} and Ramirez, {Roquc J.} and Barrow, {Robert E.} and David Herndon",
year = "1999",
month = "3",
language = "English (US)",
volume = "134",
pages = "283--286",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Growth hormone attenuates tumor necrosis factor in burned children

AU - Chrysopoulo, Minas T.

AU - Jeschke, Marc G.

AU - Ramirez, Roquc J.

AU - Barrow, Robert E.

AU - Herndon, David

PY - 1999/3

Y1 - 1999/3

N2 - Background: Recombinant human growth hormone (rhGH) has been shown to favorably modulate the acute-phase response and may improve the clinical outcome. Objective: To examine whether rhGH attenuates the elevated tumor necrosis factor α (TNF-α) levels that correlate with increased multiorgan failure and mortality in burned adults and children. Design: Twenty children with burns of greater than 40% of the total body surface area were randomly divided into 2 groups to receive placebo (n = 10) or rhGH, 0.2 mg/kg per day intramuscularly (n = 10). Setting: Pediatric burn hospital. Main Outcome Measure: Serum TNF-α levels by enzyme-linked immunoassay at baseline (day 0) and at 21 and 42 days after injury. For statistical analysis, we used the Kruskal-Wallis and Friedman tests. Results: No significant differences in age (mean ± SD, 6.2 ± 1.6 vs 5.0 ± 1.2 years) or percentage of total body surface area burn (mean ± SD, 65.1% ± 8.2% vs 57.1% ± 5.2%) could be shown between the groups given rhGH and placebo. Baseline TNF-α levels were elevated from reference values in both groups. Twenty-one and 42 days after rhGH administration, serum TNF-α levels were significantly decreased from those at baseline (P<.05). No significant decrease in TNF-α levels was observed in the placebo group (P = .5). Conclusions: Recombinant human growth hormone significantly lowers serum TNF-α levels after burn injury. This is consistent with the beneficial effect that rhGH has on the acute-phase response.

AB - Background: Recombinant human growth hormone (rhGH) has been shown to favorably modulate the acute-phase response and may improve the clinical outcome. Objective: To examine whether rhGH attenuates the elevated tumor necrosis factor α (TNF-α) levels that correlate with increased multiorgan failure and mortality in burned adults and children. Design: Twenty children with burns of greater than 40% of the total body surface area were randomly divided into 2 groups to receive placebo (n = 10) or rhGH, 0.2 mg/kg per day intramuscularly (n = 10). Setting: Pediatric burn hospital. Main Outcome Measure: Serum TNF-α levels by enzyme-linked immunoassay at baseline (day 0) and at 21 and 42 days after injury. For statistical analysis, we used the Kruskal-Wallis and Friedman tests. Results: No significant differences in age (mean ± SD, 6.2 ± 1.6 vs 5.0 ± 1.2 years) or percentage of total body surface area burn (mean ± SD, 65.1% ± 8.2% vs 57.1% ± 5.2%) could be shown between the groups given rhGH and placebo. Baseline TNF-α levels were elevated from reference values in both groups. Twenty-one and 42 days after rhGH administration, serum TNF-α levels were significantly decreased from those at baseline (P<.05). No significant decrease in TNF-α levels was observed in the placebo group (P = .5). Conclusions: Recombinant human growth hormone significantly lowers serum TNF-α levels after burn injury. This is consistent with the beneficial effect that rhGH has on the acute-phase response.

UR - http://www.scopus.com/inward/record.url?scp=0033015872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033015872&partnerID=8YFLogxK

M3 - Article

VL - 134

SP - 283

EP - 286

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 3

ER -